Boston Scientific Corporation $BSX Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP lowered its holdings in Boston Scientific Corporation (NYSE:BSX) by 18.8% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,301,828 shares of the medical equipment provider’s stock after selling 3,531,578 shares during the quarter. Wellington Management Group LLP owned 1.06% of Boston Scientific worth $653,082,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the business. Kelleher Financial Advisors acquired a new stake in shares of Boston Scientific during the 2nd quarter worth about $25,000. FWL Investment Management LLC acquired a new position in Boston Scientific in the second quarter valued at about $26,000. Swiss RE Ltd. purchased a new position in Boston Scientific during the fourth quarter worth about $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the fourth quarter valued at about $26,000. Finally, Clal Insurance Enterprises Holdings Ltd purchased a new stake in shares of Boston Scientific in the 1st quarter valued at approximately $28,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Up 0.3%

Boston Scientific stock opened at $46.82 on Friday. The firm has a market capitalization of $67.85 billion, a P/E ratio of 18.96, a P/E/G ratio of 1.02 and a beta of 0.56. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The stock’s fifty day simple moving average is $46.56 and its 200-day simple moving average is $56.65.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, topping the consensus estimate of $0.83 by $0.03. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.Boston Scientific’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.75 EPS. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, equities analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its board has authorized a stock repurchase program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to reacquire up to 6.4% of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

A number of research firms recently weighed in on BSX. Wells Fargo & Company lowered their price objective on shares of Boston Scientific from $55.00 to $50.00 and set an “equal weight” rating for the company in a research report on Thursday, July 30th. The Goldman Sachs Group set a $71.00 price target on Boston Scientific in a research note on Thursday, May 28th. Robert W. Baird set a $56.00 price target on Boston Scientific in a research report on Thursday, July 30th. Weiss Ratings cut Boston Scientific from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Tuesday, July 7th. Finally, Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Sunday, August 2nd. Twenty-four equities research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $71.62.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the stock in a transaction on Monday, August 3rd. The stock was bought at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the acquisition, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. The trade was a 13.27% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David C. Habiger acquired 2,100 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the completion of the transaction, the director owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 194,522 shares of company stock worth $9,385,210 over the last 90 days. 0.34% of the stock is owned by insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.